| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cel-Sci Corporation$1.12
+0.11 (+10.89%)
D 22Pipeline Score Richly Valued Biotech · Clinical
Market Cap
12.06 M
EPS
-3.48
P/E Ratio
-
Value Trade
212.01 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.77 M
Total Assets
17.71 M
Total Liabilities
10.83 M
Equity
6.87 M
D/E Ratio
12,345
10.94 %
Week
-63.21 %
1 Month
-71.31 %
3 Month
-76.68 %
6 Month
-99.77 %
5 Year
-100 %
All Time
Cash Data
Cash Position
1.89 M
Monthly Burn
1.77 M
Runway
0.2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
288.96 K
52 Week Range
0.89 - 13.48
% held by Insiders
7.62 %
% held by Institutions
5.37 %
Enterprise Value
18.68 M
Total Shares
8.46 M
Short %
1.72 %
Float Shares
8.12 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D22
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 21%
Micro Cap (rank 716 of 905)
Percentile RankCel-Sci Corporation faces pipeline headwinds (22/100), with $605M risk-adjusted pipeline value, led by LI in Squamous Cell Carcinoma of the Oral Cavity (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LI Monoclonal antibody | Squamous Cell Carcinoma of the Oral Cavity | Phase 3 | NCT01265849 | 48% | $605M | COMPLETED | 928 | - | - | Dec 4, 2020 | - | Aug 19, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Multikine | head and neck cancer | Phase 3 | 2025-08-13 | |||
Multikine | head and neck cancer | Phase 3 | 2025-08-13 | |||
Multikine | head and neck cancer | Phase 3 | 2025-08-13 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CVM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Cel-Sci Corporation (CVM) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CVM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CVMCEL-SCI Corporation Announces Pricing of Public Offering - May 11, 2026
CEL-SCI Corporation has announced a public offering of 6,000,000 shares priced at $1.20 each, aiming to raise approximately $7.2 million. The funds will be allocated towards the development of their cancer immunotherapy, Multikine, and for general corporate purposes. The offering is set to close on May 13, 2026, pending customary conditions.
Read more →CVMCEL-SCI Reports Fiscal First Quarter 2026 Results
CEL-SCI Corporation reported its fiscal first quarter 2026 results, highlighting key milestones including the upcoming enrollment in a U.S. FDA confirmatory trial for Multikine in head and neck cancer. The company aims to submit data for commercialization in the U.S. and other global markets. Financial results showed a reduced net loss compared to the previous year, despite ongoing expenses.
Read more →CVMCEL-SCI Reports Fiscal 2025 Results
CEL-SCI Corporation reported its fiscal 2025 results, highlighting regulatory advancements for its cancer therapy, Multikine, including a Confirmatory Registration trial approved by the FDA. The trial aims to validate previous Phase 3 study results, showing improved survival rates. The company experienced a decrease in net loss but raised concerns regarding its financial sustainability.
Read more →Competitive Position
How CVM ranks across every disease it competes inCompetitive Position is a premium feature
See how CVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial